Carson Wealth (CWM LLC)’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-809
| Closed | -$38K | – | 5350 |
|
|
2025
Q3 | $38K | Buy |
809
+585
| +261% | +$28.3K | ﹤0.01% | 3730 |
|
|
2025
Q2 | $12K | Buy |
224
+105
| +88% | +$4.77K | ﹤0.01% | 4187 |
|
|
2025
Q1 | $5K | Sell |
119
-16
| -12% | -$678 | ﹤0.01% | 4423 |
|
|
2024
Q4 | $4K | Buy |
135
+15
| +13% | +$454 | ﹤0.01% | 4265 |
|
|
2024
Q3 | $3K | Buy |
120
+89
| +287% | +$2.32K | ﹤0.01% | 4235 |
|
|
2024
Q2 | $1K | Sell |
31
-40
| -56% | -$855 | ﹤0.01% | 4296 |
|
|
2024
Q1 | $2K | Buy |
71
+1
| +1% | +$24 | ﹤0.01% | 3920 |
|
|
2023
Q4 | $2K | Buy |
70
+16
| +30% | +$316 | ﹤0.01% | 3769 |
|
|
2023
Q3 | $3K | Buy |
54
+4
| +8% | +$186 | ﹤0.01% | 3625 |
|
|
2023
Q2 | $2K | Hold |
50
| – | – | ﹤0.01% | 3741 |
|
|
2023
Q1 | $2K | Sell |
50
-7
| -12% | -$312 | ﹤0.01% | 3606 |
|
|
2022
Q4 | $3K | Buy |
57
+7
| +14% | +$300 | ﹤0.01% | 3365 |
|
|
2022
Q3 | $2K | Hold |
50
| – | – | ﹤0.01% | 3405 |
|
|
2022
Q2 | $0 | Sell |
50
-66
| -57% | -$688 | ﹤0.01% | 3750 |
|
|
2022
Q1 | $2K | Buy |
116
+14
| +14% | +$245 | ﹤0.01% | 3123 |
|
|
2021
Q4 | $2K | Buy |
+102
| New | +$2.26K | ﹤0.01% | 3079 |
|
Other funds holding AKRO
Carson Wealth (CWM LLC)'s AKRO Position: Q4 2025 in Review
Carson Wealth (CWM LLC) sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 809 shares — an estimated $38K sold.
Carson Wealth (CWM LLC) first reported a position in AKRO in Q4 2021 and held it in 16 quarters. The position peaked at $38K in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Carson Wealth (CWM LLC) reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Carson Wealth (CWM LLC) sold 809 Akero Therapeutics shares in Q4 2025, an estimated $38K.
- Carson Wealth (CWM LLC) first reported a position in Akero Therapeutics in Q4 2021 and held it in 16 quarters.
- Carson Wealth (CWM LLC)'s Akero Therapeutics position peaked at $38K in Q3 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Carson Wealth (CWM LLC)'s 13F filing for Q4 2025, filed 26 Jan 2026.